The Technical Analyst
Rain Therapeutics Inc. [RAIN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Rain Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.63% $1.210
America/New_York / 25 jan 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 44.01 mill |
| EPS: | -2.07 |
| P/E: | -0.585 |
| Earnings Date: | Mar 07, 2024 |
| SharesOutstanding: | 36.38 mill |
| Avg Daily Volume: | 0.238 mill |
| RATING 2024-01-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.585 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.585 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.172 - 1.248 ( +/- 3.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-26 | Tang Kevin C | Sell | 3 850 513 | Common Stock |
| 2024-01-25 | Bvf Partners L P/il | Sell | 185 388 | Common Stock, $0.001 par value |
| 2024-01-25 | Bvf Partners L P/il | Sell | 341 547 | Non-Voting Common Stock, $0.001 par value |
| 2024-01-26 | Bvf Partners L P/il | Sell | 35 000 | Stock Option (Right to Buy) |
| 2024-01-26 | Bvf Partners L P/il | Sell | 20 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -56.83 |
| Last 98 transactions |
| Buy: 6 387 020 | Sell: 11 238 556 |
Forecast:
01:40 - $1.270
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.210 (-1.63% ) |
| Volume | 3.70 mill |
| Avg. Vol. | 0.238 mill |
| % of Avg. Vol | 1 552.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RAIN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RAIN
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Latest Press Releases
2024-01-26 08:49:00 - Press Release
Pathos Ai Completes Acquisition Of Rain Oncology
Chicago--(business wire)--pathos ai, inc. (“pathos”) today announced that it has, through its wholly owned subsidiary wk merger sub, inc. (“merger sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of rain oncology inc. (nasdaq: rain) (“rain”) for $1.16 per share in cash plus one contingent value right per share (each, a “cvr”), which cvr shall represent the right to receive potential payments pursuant to the terms and subject to the conditions.
2024-01-04 21:08:00 - Press Release
Rain Oncology Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Rain Oncology Inc. - Rain
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of rain oncology inc. (nasdaqgs: rain) to pathos ai, inc. under the terms of the proposed transaction, shareholders of rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of rain that they own. ksf is seeking to deter.
2023-12-18 14:21:00 - Press Release
Rain Oncology Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Rain Oncology Inc. - Rain
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of rain oncology inc. (nasdaqgs: rain) to pathos ai, inc. under the terms of the proposed transaction, shareholders of rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of rain that they own. ksf is seeking to deter.
2023-12-14 10:41:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Rain Oncology Inc. Has Obtained A Fair Price In Its Transaction With Pathos
Milwaukee , dec. 14, 2023 /prnewswire/ -- ademi llp is investigating rain (nasdaq: rain) for possible breaches of fiduciary duty and other violations of law in its transaction with pathos. click here to learn how to join the https://www.ademilaw.com/case/rain-oncology-inc or call guri ademi toll-free at 866-264-3995.
2023-12-14 02:42:00 - Press Release
Rain Stock Alert: Halper Sadeh Llc Is Investigating Whether The Sale Of Rain Oncology Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of rain oncology inc. (nasdaq: rain) to pathos ai, inc. for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share is fair to rain shareholders. halper sadeh encourages rain shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060.
Latest News
2023-10-16 10:35:20 - PennyStocks
3 Top Penny Stocks to Buy According To Insiders In October
Penny stocks, defined as stocks trading under $5 per share, offer traders huge upside potential but also carry significant risks. One strategy used by some investors to identify promising penny stocks is tracking insider trading activity through SEC filings.
2023-08-10 18:39:03 - Seeking Alpha
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
Rain Oncology Inc. (NASDAQ:RAIN ) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP, Finance Robert Doebele - CSO Conference Call Participants Ashiq Mubarack - Citigroup Joe Catanzaro - Piper Sandler Anshul Dhankher - LifeSci Capital Avantika Joshi - Mizuho Securities Mitchell Kapoor - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Rain Oncology Inc. Second Quarter 2023 Earnings Conference Call.
2023-07-26 08:00:00 - GlobeNewsWire
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.
2023-07-18 16:55:42 - GuruFocus
Monish Pabrai on Finding Multi-Baggers and Intrinsic Valuation
Mohnish Pabrai (Trades, Portfolio) is a legendary investor and the founder of Pabrai funds.
2023-05-22 15:15:00 - The Motley Fool
Why Shares of Rain Oncology Are Plummeting Today
Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.
2023-05-22 11:07:40 - InvestorPlace
Why Is RAIN Stock Down 87% Today?
Rain Oncology (NASDAQ: RAIN ) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company's Phase 3 MANTRA trial failed to meet its primary endpoint.
2023-05-13 03:42:09 - Seeking Alpha
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
Rain Oncology, Inc. (NASDAQ:RAIN ) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Bryce - CMO Nelson Cabatuan - SVP, Finance Conference Call Participants Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Joe Catanzaro - Piper Sandler Soumit Roy - Jones Trading Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Faisal Khurshid - SVB Securities Mitchell Kapoor - H.C. Wainwright Avantika Joshi - Mizuho Securities Tony Butler - EF Hutton Operator Greetings, and welcome to the Rain Oncology, Inc. First Quarter 2023 Earnings Call.
2023-04-27 02:36:07 - Seeking Alpha
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
2023-04-26 14:34:23 - Seeking Alpha
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
2023-03-09 21:04:08 - Seeking Alpha
Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript
Rain Oncology Inc. (NASDAQ:RAIN ) Q4 2022 Results Conference Call March 9, 2023 5:00 PM ET Company Participants Dan Ferry - LifeSci Advisors Avanish Vellanki - Chief Executive Officer Robert Doebele - Chief Scientific Officer Richard Bryce - Chief Medical Officer Nelson Cabatuan - Senior Vice President-Finance Conference Call Participants Michael Schmidt - Guggenheim Partners Joseph Catanzaro - Piper Sandler Soumit Roy - Jones Research Jeff Jones - Oppenheimer Yigal Nochomovitz - Citigroup Sam Slutsky - Lifesci Capital Graig Suvannavejh - Mizuho Securities Mitchell Kapoor - H.C. Wainwright Tony Butler - EF Hutton Kumar Raja - Roth Capital Partners Operator Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call.